The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 4 rounds in the feed, most often at Series A and in Biotech.
Venture capitalNaarden, The Netherlandsbiogenerationventures.comRounds from 2023-11-13 to 2026-11-11
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
VectorY Therapeutics A clinical-stage biotechnology company pioneering vectorized antibody therapies for neurodegenerative diseases | Series A Verified against 1 of 10 sources | $82.9M | 2026-11-11 | [ PART ] |
Rouge Therapeutics A provider of first-in-class disease-modifying therapies designed to restore vascular integrity | Series A |
| $58M |
| 2026-10-06 |
| [ LEAD ] |
Azafaros Azafaros develops therapeutics for patients with rare metabolic disorders, particularly those affecting the lysosomal storage system. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $146.7M | 2025-05-13 | [ PART ] |
VectorY Therapeutics A clinical-stage biotechnology company pioneering vectorized antibody therapies for neurodegenerative diseases | Series A Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $137.6M | 2023-11-13 | [ PART ] |